TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Johnson Fistel, Pllp
Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment

A class action lawsuit has been filed against Skye Bioscience alleging false and misleading statements about their drug candidate nimacimab's effectiveness and prospects, with investors suffering substantial damages on October 3, 2025.

Insights
SKYE   negative

The lawsuit alleges the company made materially false statements about their drug's effectiveness, overstated clinical and commercial prospects, and caused investors to suffer substantial damages